• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Owen Mumford appoints new director of R&D

June 15, 2022 By Sean Whooley

Owen MumfordOwen Mumford announced today that it appointed Bal Johal as its director of research and development, effective next month.

Johal will become the director of R&D for the Woodstock, United Kingdom-based developer of medical devices, including the Aidaptus auto-injector, on July 4, 2022.

She has most recently served as VP of product development, quality, regulatory and medical with Circassia. Before that position, she held roles within R&D at GlaxoSmithKline, Pfizer and Mudipharma Research, according to a news release.

“To join Owen Mumford at this time is very exciting,” Johal said in the release. “With a combination of progress already made and some very talented people within the organization, I can see that we will be able to deliver a high standard of success and innovation that will have a truly positive impact.”

Owen Mumford said R&D remains at the heart of its efforts, representing a “major pillar” in the company’s strategic direction and development.

The company feels the appointment of Johal into the role heading up R&D will enhance the quality and strength of its existing pipeline of products while also securing a “well-defined path” to offer new ambitions in innovation, sustainable product design, life-cycle analysis and increased positive impact on healthcare professionals and patient experience.

“We welcome Bal very warmly into our business,” Owen Mumford Managing Director Jarl Severn said. “She has the background, experience and drive to continue to accelerate the innovation and forward-thinking that will see us achieve ambitious growth and set us apart from the competition.”

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Personnel Tagged With: Owen Mumford, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS